Shots:
- The CHMP has recommended marketing authorization for Lupin’s Ranluspec, in both vial and PFS forms, a biosimilar version of Lucentis (ranibizumab)
- Opinion was supported by analytical similarity data and a global P-III trial (n=600 pts) in neovascular AMD across the US, EU, Russia, and India
- Under the agreement, Lupin’s biosimilar ranibizumab will be marketed by Sandoz across the EU (excluding Germany), with Sandoz AG and Biogaran commercializing it in France
Ref: Lupin | Image: Lupin| Press Release
Related News: Lupin and Valorum Biologics Join Forces to Commercialize Armlupeg (Biosimilar, Neulasta) in the US
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
